Last updated on November 2018

Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

Brief description of study

The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.

Clinical Study Identifier: NCT02273375

Contact Investigators or Research Sites near you

Start Over

Tetsuya Mitsudomi

Kinki University Hospital Faculty of Medicine
Osaka-Sayama, Japan
  Connect »

Shinji Atagi

National Hospital Organization Kinki-Chuo
Sakai, Japan
  Connect »